|Mr. Paul M. Michaels||President & Executive Chairman||335.39k||N/A||1967|
|Mr. I. Richard Garr Esq., J.D.||CEO, CFO, Principal Accounting Officer & General Counsel||455.39k||N/A||1953|
|Dr. Barry A. Ginsberg B.A., B.S.||Chief Strategy Officer, Vice Chairman and Member of Scientific & Clinical Advisory Board||335.39k||N/A||1958|
|Mr. Pam Bisikirski||Vice President of Communications||N/A||N/A||N/A|
|Dr. Ronald Bordens Ph.D.||Executive VP of Process Product Drug Development and Member of Scientific & Clinical Advisory Board||N/A||N/A||N/A|
Curative Biotechnology, Inc. operates as a development-stage biomedical company. The company develops pipeline focusing on therapeutic areas, such as infectious diseases, oncology, and degenerative eye disease. Its pipeline candidates include IMT504, a novel immune therapy to treat rabies and an adjuvant for vaccines; CUBT906, a fully humanized CD56 monoclonal antibody carrying a pyrrolobenzodiazepine dimer directly to the tumor site to kill the tumor by inhibiting tumor growth and migration of the tumor; and Metformin Reformulation for the treatment of degenerative eye disease. The company has a licensing and co-development agreement with Mid-Atlantic BioTherapeutics, Inc. to develop IMT504 to treat late-stage rabies and COVID-19 vaccine. The company was formerly known as Connectyx Technologies Holdings Group, Inc. and changed its name to Curative Biotechnology, Inc. in November 2020. Curative Biotechnology, Inc. was founded in 1995 and is headquartered in Boca Raton, Florida.
Curative Biotechnology, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.